Angiopoietins as serum biomarkers for lymphatic anomalies
- 478 Downloads
Vascular anomalies can cause significant morbidity and mortality. Advances in diagnosis will be improved if noninvasive biomarkers can be identified, as obtaining a tissue biopsy can worsen the disease and precipitate complications. The goal of this study was to identify biomarkers for vascular anomaly patients to aid diagnosis and potentially give insights into pathogenesis. Blood was collected at baseline and then 6 and 12 months after treatment with the mTOR inhibitor sirolimus. Patients groups included generalized lymphatic anomaly (GLA), kaposiform lymphangiomatosis (KLA) and kaposiform hemangioendothelioma (KHE) with or without the Kasabach–Merritt phenomenon (KMP) coagulopathy. Serum was obtained from healthy controls selected to match the age and sex of the patients (21 days–28.5 years; 42% males; 58% females). Angiogenic and lymphangiogenic factors (VEGF-A, C, D, Ang-1 and Ang-2) were measured in serum using ELISA. In lymphatic anomaly patients, baseline levels of VEGF-A and VEGF-D were not different compared to controls. Angiopoietin-2 (Ang-2) levels were near controls levels in GLA patients but 10-fold greater in KLA patients and 14-fold greater in KHE patients when the KMP coagulopathy was present but not when it was absent. VEGF-C and angiopoietin-1 (Ang-1) levels were lower in KHE patients with KMP. Our analyses suggest that Ang-2 and Ang-1 can be used as biomarkers to help identify KLA and KHE patients with KMP coagulopathy with high sensitivity and specificity. After 12 months of sirolimus treatment, Ang-2 levels were lower in KLA and KHE with KMP patients compared to baseline levels and with most patients showing a clinical response. Hence, serum Ang-2 and Ang-1 levels may help in the diagnosis of patients with lymphatic anomalies and are concordant to sirolimus response.
KeywordsVascular anomalies Generalized lymphatic anomaly Kaposiform lymphangiomatosis Kaposiform hemangioendothelioma Sirolimus Kasabach–Merritt
General lymphatic anomaly
The authors would like to thank Tricia Pastura for assistance with the ELISA.
Grant funding support was received from the Federal Drug Administration (5RO1FD003712-04) and the Lymphatic Malformation Institute.
- 1.Wassef M, Blei F, Adams D, Alomari A, Baselga E, Berenstein A, Burrows P, Frieden IJ, Garzon MC, Lopez-Gutierrez JC, Lord DJ, Mitchel S, Powell J, Prendiville J, Vikkula M, Board I, Scientific C (2015) Vascular anomalies classification: recommendations from the international society for the study of vascular anomalies. Pediatrics 136(1):e203–e214. doi: 10.1542/peds.2014-3673 CrossRefPubMedGoogle Scholar
- 2.Marler JJ, Fishman SJ, Kilroy SM, Fang J, Upton J, Mulliken JB, Burrows PE, Zurakowski D, Folkman J, Moses MA (2005) Increased expression of urinary matrix metalloproteinases parallels the extent and activity of vascular anomalies. Pediatrics 116(1):38–45. doi: 10.1542/peds.2004-1518 CrossRefPubMedGoogle Scholar
- 3.Adams DM, Trenor CC III, Hammill AM, Vinks AA, Patel MN, Chaudry G, Wentzel MS, Mobberley-Schuman PS, Campbell LM, Brookbank C, Gupta A, Chute C, Eile J, McKenna J, Merrow AC, Fei L, Hornung L, Seid M, Dasgupta AR, Dickie BH, Elluru RG, Lucky AW, Weiss B, Azizkhan RG (2016) Efficacy and safety of sirolimus in the treatment of complicated vascular anomalies. Pediatrics 137(2):1–10. doi: 10.1542/peds.2015-3257 Google Scholar
- 8.ISSVA Classification of Vascular Anomalies ©2014 International Society for the Study of Vascular Anomalies Available at http://www.issva.org/classification. Accessed April 2014
- 13.Lackner H, Karastaneva A, Schwinger W, Benesch M, Sovinz P, Seidel M, Sperl D, Lanz S, Haxhija E, Reiterer F, Sorantin E, Urban CE (2015) Sirolimus for the treatment of children with various complicated vascular anomalies. Eur J Pediatr 174(12):1579–1584. doi: 10.1007/s00431-015-2572-y CrossRefPubMedGoogle Scholar
- 24.Young LR, Vandyke R, Gulleman PM, Inoue Y, Brown KK, Schmidt LS, Linehan WM, Hajjar F, Kinder BW, Trapnell BC, Bissler JJ, Franz DN, McCormack FX (2010) Serum vascular endothelial growth factor-D prospectively distinguishes lymphangioleiomyomatosis from other diseases. Chest 138(3):674–681. doi: 10.1378/chest.10-0573 CrossRefPubMedPubMedCentralGoogle Scholar
- 27.Venables WN, Ripley BD (2002) Modern applied statistics with S, 4th edn. Springer, New York, ISBN:0-387-95457-0Google Scholar
- 30.Gale NW, Thurston G, Hackett SF, Renard R, Wang Q, McClain J, Martin C, Witte C, Witte MH, Jackson D, Suri C, Campochiaro PA, Wiegand SJ, Yancopoulos GD (2002) Angiopoietin-2 is required for postnatal angiogenesis and lymphatic patterning, and only the latter role is rescued by Angiopoietin-1. Dev Cell 3(3):411–423CrossRefPubMedGoogle Scholar
- 34.Xie Z, Ghosh CC, Patel R, Iwaki S, Gaskins D, Nelson C, Jones N, Greipp PR, Parikh SM, Druey KM (2012) Vascular endothelial hyperpermeability induces the clinical symptoms of Clarkson disease (the systemic capillary leak syndrome). Blood 119(18):4321–4332. doi: 10.1182/blood-2011-08-375816 CrossRefPubMedPubMedCentralGoogle Scholar
- 35.Yu Y, Varughese J, Brown LF, Mulliken JB, Bischoff J (2001) Increased Tie2 expression, enhanced response to angiopoietin-1, and dysregulated angiopoietin-2 expression in hemangioma-derived endothelial cells. Am J Pathol 159(6):2271–2280. doi: 10.1016/S0002-9440(10)63077-5 CrossRefPubMedPubMedCentralGoogle Scholar